An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone When Administered Once or Twice Daily in Combination with Glyburide to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)
Diabetes Mellitus, Type 2
Phase 3
A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
June 2014